Acer Therapeutics rises on agreement with FDA for late-stage trial
09/05/2022 14:26
** Drug developer Acer Therapeutics' shares ACER.O up 8.1%
at $2.26 premarket
** Co announces agreement with FDA on special protocol
assessment for its late-stage trial of edsivo in vascular
Ehlers-Danlos syndrome patients, a genetic disease which can
cause abnormal fragility in blood vessels urn:newsml:reuters.com:*:nGNXbMLcC6
** Co plans to start trial by end of Q2
** All 3 brokerages covering ACER rate the stock "buy";
their median PT is $10
** Stock down 8% YTD up to last close
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31